Allergic Rhinitis Drugs Comprehensive Study by Type (Corticosteroids, Antihistamines, Vasoconstrictors, Pratropium Bromide, Others (Leukotrienes, Cromoglycate)), Application (Non-Allergic Rhinitis, Mixed Rhinitis, Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Others), Treatment (Oral Antihistamines, Local Steroids) Players and Region - Global Market Outlook to 2024

Allergic Rhinitis Drugs Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Allergic Rhinitis Drugs Market Overview:
Allergic rhinitis is a high-prevalence disease in many developed countries, affecting about 10±20% of the general population. Patients with allergic rhinitis may have both nasal and non-nasal symptoms. The main nasal symptoms of allergic rhinitis are nasal itching (i.e., nasal pruritus), sneezing, rhinorrhea, and nasal congestion. Rhinitis is a disease characterized by inflammation of the nasal mucous membrane. As inflammation cannot be identified by ordinary diagnostic procedures, a clinical diagnosis of rhinitis is based on the symptoms of sneezing, rhinorrhea and nasal blockage. Additional symptoms such as headache, impaired smell, and conjunctival symptoms can be associated. Some of the key players profiled in the study are Glaxosmithkline (United Kingdom), Merck (United States), Sanofi (France), Alcon (United States), Adamis Pharmaceuticals (United States), Belcher Pharmaceuticals (United States), Dr Reddy's Laboratories (India), Mitsubishi Tanabe Pharma (Japan), Novartis (Switzerland), Pfizer (United States), UCB (Belgium), Kyowo Hako Kirin (Japan) and Stallergenes Greer (United Kingdom).

On the basis of geography, the market of Allergic Rhinitis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Oral Antihistamines will boost the Allergic Rhinitis Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Demand For Over the Counter Medicines
  • Growing Number of Chemical Mediators

Market Trend
  • Rising the Incidence of Allergic Rhinitis

Restraints
  • Vasoconstrictors are Rarely Used in Europe Due To Their Poor Therapeutic Index

Opportunities
  • Increasing Awareness about Allergic Rhinitis

Challenges
  • Side Effects of Drug Treatment to the Diseased Tissue


On June 17, 2019 - Pfizer Inc. and Array BioPharma Inc. has announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.


Target Audience:
Manufacturers of Allergic Rhinitis Drug, Suppliers of Allergic Rhinitis Drug, Wholesalers, Distributors and Retailers of Allergic Rhinitis Drug, Healthcare Industry, Research Organization, Regulatory Bodies and Governmental Bodies

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Allergic Rhinitis Drugs market on the basis of product [Corticosteroids, Antihistamines, Vasoconstrictors, Pratropium Bromide and Others [Leukotrienes, Cromoglycate]] , application [Non-Allergic Rhinitis, Mixed Rhinitis, Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Allergic Rhinitis Drugs market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Allergic Rhinitis Drugs industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Allergic Rhinitis Drugs market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.

Report Objectives / Segmentation Covered

By Type
  • Corticosteroids
  • Antihistamines
  • Vasoconstrictors
  • Pratropium Bromide
  • Others [Leukotrienes, Cromoglycate]
By Application
  • Non-Allergic Rhinitis
  • Mixed Rhinitis
  • Seasonal Allergic Rhinitis
  • Perennial Allergic Rhinitis
  • Others
By Treatment
  • Oral Antihistamines
  • Local Steroids

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand For Over the Counter Medicines
      • 3.2.2. Growing Number of Chemical Mediators
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of Drug Treatment to the Diseased Tissue
    • 3.4. Market Trends
      • 3.4.1. Rising the Incidence of Allergic Rhinitis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Allergic Rhinitis Drugs, by Type, Application, Treatment and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Allergic Rhinitis Drugs (Value)
      • 5.2.1. Global Allergic Rhinitis Drugs by: Type (Value)
        • 5.2.1.1. Corticosteroids
        • 5.2.1.2. Antihistamines
        • 5.2.1.3. Vasoconstrictors
        • 5.2.1.4. Pratropium Bromide
        • 5.2.1.5. Others [Leukotrienes, Cromoglycate]
      • 5.2.2. Global Allergic Rhinitis Drugs by: Application (Value)
        • 5.2.2.1. Non-Allergic Rhinitis
        • 5.2.2.2. Mixed Rhinitis
        • 5.2.2.3. Seasonal Allergic Rhinitis
        • 5.2.2.4. Perennial Allergic Rhinitis
        • 5.2.2.5. Others
      • 5.2.3. Global Allergic Rhinitis Drugs by: Treatment (Value)
        • 5.2.3.1. Oral Antihistamines
        • 5.2.3.2. Local Steroids
      • 5.2.4. Global Allergic Rhinitis Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Allergic Rhinitis Drugs (Volume)
      • 5.3.1. Global Allergic Rhinitis Drugs by: Type (Volume)
        • 5.3.1.1. Corticosteroids
        • 5.3.1.2. Antihistamines
        • 5.3.1.3. Vasoconstrictors
        • 5.3.1.4. Pratropium Bromide
        • 5.3.1.5. Others [Leukotrienes, Cromoglycate]
      • 5.3.2. Global Allergic Rhinitis Drugs by: Application (Volume)
        • 5.3.2.1. Non-Allergic Rhinitis
        • 5.3.2.2. Mixed Rhinitis
        • 5.3.2.3. Seasonal Allergic Rhinitis
        • 5.3.2.4. Perennial Allergic Rhinitis
        • 5.3.2.5. Others
      • 5.3.3. Global Allergic Rhinitis Drugs by: Treatment (Volume)
        • 5.3.3.1. Oral Antihistamines
        • 5.3.3.2. Local Steroids
      • 5.3.4. Global Allergic Rhinitis Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Allergic Rhinitis Drugs (Price)
      • 5.4.1. Global Allergic Rhinitis Drugs by: Type (Price)
  • 6. Allergic Rhinitis Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Glaxosmithkline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Alcon (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Adamis Pharmaceuticals (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Belcher Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Dr Reddy's Laboratories (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mitsubishi Tanabe Pharma (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. UCB (Belgium)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Kyowo Hako Kirin (Japan)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Stallergenes Greer (United Kingdom)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Allergic Rhinitis Drugs Sale, by Type, Application, Treatment and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Allergic Rhinitis Drugs (Value)
      • 7.2.1. Global Allergic Rhinitis Drugs by: Type (Value)
        • 7.2.1.1. Corticosteroids
        • 7.2.1.2. Antihistamines
        • 7.2.1.3. Vasoconstrictors
        • 7.2.1.4. Pratropium Bromide
        • 7.2.1.5. Others [Leukotrienes, Cromoglycate]
      • 7.2.2. Global Allergic Rhinitis Drugs by: Application (Value)
        • 7.2.2.1. Non-Allergic Rhinitis
        • 7.2.2.2. Mixed Rhinitis
        • 7.2.2.3. Seasonal Allergic Rhinitis
        • 7.2.2.4. Perennial Allergic Rhinitis
        • 7.2.2.5. Others
      • 7.2.3. Global Allergic Rhinitis Drugs by: Treatment (Value)
        • 7.2.3.1. Oral Antihistamines
        • 7.2.3.2. Local Steroids
      • 7.2.4. Global Allergic Rhinitis Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Allergic Rhinitis Drugs (Volume)
      • 7.3.1. Global Allergic Rhinitis Drugs by: Type (Volume)
        • 7.3.1.1. Corticosteroids
        • 7.3.1.2. Antihistamines
        • 7.3.1.3. Vasoconstrictors
        • 7.3.1.4. Pratropium Bromide
        • 7.3.1.5. Others [Leukotrienes, Cromoglycate]
      • 7.3.2. Global Allergic Rhinitis Drugs by: Application (Volume)
        • 7.3.2.1. Non-Allergic Rhinitis
        • 7.3.2.2. Mixed Rhinitis
        • 7.3.2.3. Seasonal Allergic Rhinitis
        • 7.3.2.4. Perennial Allergic Rhinitis
        • 7.3.2.5. Others
      • 7.3.3. Global Allergic Rhinitis Drugs by: Treatment (Volume)
        • 7.3.3.1. Oral Antihistamines
        • 7.3.3.2. Local Steroids
      • 7.3.4. Global Allergic Rhinitis Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Allergic Rhinitis Drugs (Price)
      • 7.4.1. Global Allergic Rhinitis Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Allergic Rhinitis Drugs: by Type(USD Million)
  • Table 2. Allergic Rhinitis Drugs Corticosteroids , by Region USD Million (2013-2018)
  • Table 3. Allergic Rhinitis Drugs Antihistamines , by Region USD Million (2013-2018)
  • Table 4. Allergic Rhinitis Drugs Vasoconstrictors , by Region USD Million (2013-2018)
  • Table 5. Allergic Rhinitis Drugs Pratropium Bromide , by Region USD Million (2013-2018)
  • Table 6. Allergic Rhinitis Drugs Others [Leukotrienes, Cromoglycate] , by Region USD Million (2013-2018)
  • Table 7. Allergic Rhinitis Drugs: by Application(USD Million)
  • Table 8. Allergic Rhinitis Drugs Non-Allergic Rhinitis , by Region USD Million (2013-2018)
  • Table 9. Allergic Rhinitis Drugs Mixed Rhinitis , by Region USD Million (2013-2018)
  • Table 10. Allergic Rhinitis Drugs Seasonal Allergic Rhinitis , by Region USD Million (2013-2018)
  • Table 11. Allergic Rhinitis Drugs Perennial Allergic Rhinitis , by Region USD Million (2013-2018)
  • Table 12. Allergic Rhinitis Drugs Others , by Region USD Million (2013-2018)
  • Table 13. Allergic Rhinitis Drugs: by Treatment(USD Million)
  • Table 14. Allergic Rhinitis Drugs Oral Antihistamines , by Region USD Million (2013-2018)
  • Table 15. Allergic Rhinitis Drugs Local Steroids , by Region USD Million (2013-2018)
  • Table 16. South America Allergic Rhinitis Drugs, by Country USD Million (2013-2018)
  • Table 17. South America Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 18. South America Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 19. South America Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 20. Brazil Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 21. Brazil Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 22. Brazil Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 23. Argentina Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 24. Argentina Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 25. Argentina Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 26. Rest of South America Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 27. Rest of South America Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 28. Rest of South America Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 29. Asia Pacific Allergic Rhinitis Drugs, by Country USD Million (2013-2018)
  • Table 30. Asia Pacific Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 31. Asia Pacific Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 32. Asia Pacific Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 33. China Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 34. China Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 35. China Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 36. Japan Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 37. Japan Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 38. Japan Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 39. India Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 40. India Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 41. India Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 42. South Korea Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 43. South Korea Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 44. South Korea Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 45. Taiwan Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 46. Taiwan Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 47. Taiwan Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 48. Australia Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 49. Australia Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 50. Australia Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 51. Rest of Asia-Pacific Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 52. Rest of Asia-Pacific Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 53. Rest of Asia-Pacific Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 54. Europe Allergic Rhinitis Drugs, by Country USD Million (2013-2018)
  • Table 55. Europe Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 56. Europe Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 57. Europe Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 58. Germany Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 59. Germany Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 60. Germany Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 61. France Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 62. France Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 63. France Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 64. Italy Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 65. Italy Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 66. Italy Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 67. United Kingdom Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 68. United Kingdom Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 69. United Kingdom Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 70. Netherlands Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 71. Netherlands Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 72. Netherlands Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 73. Rest of Europe Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 74. Rest of Europe Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 75. Rest of Europe Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 76. MEA Allergic Rhinitis Drugs, by Country USD Million (2013-2018)
  • Table 77. MEA Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 78. MEA Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 79. MEA Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 80. Middle East Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 81. Middle East Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 82. Middle East Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 83. Africa Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 84. Africa Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 85. Africa Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 86. North America Allergic Rhinitis Drugs, by Country USD Million (2013-2018)
  • Table 87. North America Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 88. North America Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 89. North America Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 90. United States Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 91. United States Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 92. United States Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 93. Canada Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 94. Canada Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 95. Canada Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 96. Mexico Allergic Rhinitis Drugs, by Type USD Million (2013-2018)
  • Table 97. Mexico Allergic Rhinitis Drugs, by Application USD Million (2013-2018)
  • Table 98. Mexico Allergic Rhinitis Drugs, by Treatment USD Million (2013-2018)
  • Table 99. Allergic Rhinitis Drugs Sales: by Type(K Tons)
  • Table 100. Allergic Rhinitis Drugs Sales Corticosteroids , by Region K Tons (2013-2018)
  • Table 101. Allergic Rhinitis Drugs Sales Antihistamines , by Region K Tons (2013-2018)
  • Table 102. Allergic Rhinitis Drugs Sales Vasoconstrictors , by Region K Tons (2013-2018)
  • Table 103. Allergic Rhinitis Drugs Sales Pratropium Bromide , by Region K Tons (2013-2018)
  • Table 104. Allergic Rhinitis Drugs Sales Others [Leukotrienes, Cromoglycate] , by Region K Tons (2013-2018)
  • Table 105. Allergic Rhinitis Drugs Sales: by Application(K Tons)
  • Table 106. Allergic Rhinitis Drugs Sales Non-Allergic Rhinitis , by Region K Tons (2013-2018)
  • Table 107. Allergic Rhinitis Drugs Sales Mixed Rhinitis , by Region K Tons (2013-2018)
  • Table 108. Allergic Rhinitis Drugs Sales Seasonal Allergic Rhinitis , by Region K Tons (2013-2018)
  • Table 109. Allergic Rhinitis Drugs Sales Perennial Allergic Rhinitis , by Region K Tons (2013-2018)
  • Table 110. Allergic Rhinitis Drugs Sales Others , by Region K Tons (2013-2018)
  • Table 111. Allergic Rhinitis Drugs Sales: by Treatment(K Tons)
  • Table 112. Allergic Rhinitis Drugs Sales Oral Antihistamines , by Region K Tons (2013-2018)
  • Table 113. Allergic Rhinitis Drugs Sales Local Steroids , by Region K Tons (2013-2018)
  • Table 114. South America Allergic Rhinitis Drugs Sales, by Country K Tons (2013-2018)
  • Table 115. South America Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 116. South America Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 117. South America Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 118. Brazil Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 119. Brazil Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 120. Brazil Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 121. Argentina Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 122. Argentina Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 123. Argentina Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 124. Rest of South America Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 125. Rest of South America Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 126. Rest of South America Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 127. Asia Pacific Allergic Rhinitis Drugs Sales, by Country K Tons (2013-2018)
  • Table 128. Asia Pacific Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 129. Asia Pacific Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 130. Asia Pacific Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 131. China Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 132. China Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 133. China Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 134. Japan Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 135. Japan Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 136. Japan Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 137. India Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 138. India Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 139. India Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 140. South Korea Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 141. South Korea Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 142. South Korea Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 143. Taiwan Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 144. Taiwan Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 145. Taiwan Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 146. Australia Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 147. Australia Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 148. Australia Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 149. Rest of Asia-Pacific Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 150. Rest of Asia-Pacific Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 151. Rest of Asia-Pacific Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 152. Europe Allergic Rhinitis Drugs Sales, by Country K Tons (2013-2018)
  • Table 153. Europe Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 154. Europe Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 155. Europe Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 156. Germany Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 157. Germany Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 158. Germany Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 159. France Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 160. France Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 161. France Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 162. Italy Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 163. Italy Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 164. Italy Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 165. United Kingdom Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 166. United Kingdom Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 167. United Kingdom Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 168. Netherlands Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 169. Netherlands Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 170. Netherlands Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 171. Rest of Europe Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 172. Rest of Europe Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 173. Rest of Europe Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 174. MEA Allergic Rhinitis Drugs Sales, by Country K Tons (2013-2018)
  • Table 175. MEA Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 176. MEA Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 177. MEA Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 178. Middle East Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 179. Middle East Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 180. Middle East Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 181. Africa Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 182. Africa Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 183. Africa Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 184. North America Allergic Rhinitis Drugs Sales, by Country K Tons (2013-2018)
  • Table 185. North America Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 186. North America Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 187. North America Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 188. United States Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 189. United States Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 190. United States Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 191. Canada Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 192. Canada Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 193. Canada Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 194. Mexico Allergic Rhinitis Drugs Sales, by Type K Tons (2013-2018)
  • Table 195. Mexico Allergic Rhinitis Drugs Sales, by Application K Tons (2013-2018)
  • Table 196. Mexico Allergic Rhinitis Drugs Sales, by Treatment K Tons (2013-2018)
  • Table 197. Allergic Rhinitis Drugs: by Type(USD/Units)
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Allergic Rhinitis Drugs: by Type(USD Million)
  • Table 212. Allergic Rhinitis Drugs Corticosteroids , by Region USD Million (2019-2024)
  • Table 213. Allergic Rhinitis Drugs Antihistamines , by Region USD Million (2019-2024)
  • Table 214. Allergic Rhinitis Drugs Vasoconstrictors , by Region USD Million (2019-2024)
  • Table 215. Allergic Rhinitis Drugs Pratropium Bromide , by Region USD Million (2019-2024)
  • Table 216. Allergic Rhinitis Drugs Others [Leukotrienes, Cromoglycate] , by Region USD Million (2019-2024)
  • Table 217. Allergic Rhinitis Drugs: by Application(USD Million)
  • Table 218. Allergic Rhinitis Drugs Non-Allergic Rhinitis , by Region USD Million (2019-2024)
  • Table 219. Allergic Rhinitis Drugs Mixed Rhinitis , by Region USD Million (2019-2024)
  • Table 220. Allergic Rhinitis Drugs Seasonal Allergic Rhinitis , by Region USD Million (2019-2024)
  • Table 221. Allergic Rhinitis Drugs Perennial Allergic Rhinitis , by Region USD Million (2019-2024)
  • Table 222. Allergic Rhinitis Drugs Others , by Region USD Million (2019-2024)
  • Table 223. Allergic Rhinitis Drugs: by Treatment(USD Million)
  • Table 224. Allergic Rhinitis Drugs Oral Antihistamines , by Region USD Million (2019-2024)
  • Table 225. Allergic Rhinitis Drugs Local Steroids , by Region USD Million (2019-2024)
  • Table 226. South America Allergic Rhinitis Drugs, by Country USD Million (2019-2024)
  • Table 227. South America Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 228. South America Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 229. South America Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 230. Brazil Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 231. Brazil Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 232. Brazil Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 233. Argentina Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 234. Argentina Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 235. Argentina Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 236. Rest of South America Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 237. Rest of South America Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 238. Rest of South America Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 239. Asia Pacific Allergic Rhinitis Drugs, by Country USD Million (2019-2024)
  • Table 240. Asia Pacific Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 241. Asia Pacific Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 242. Asia Pacific Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 243. China Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 244. China Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 245. China Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 246. Japan Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 247. Japan Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 248. Japan Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 249. India Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 250. India Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 251. India Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 252. South Korea Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 253. South Korea Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 254. South Korea Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 255. Taiwan Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 256. Taiwan Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 257. Taiwan Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 258. Australia Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 259. Australia Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 260. Australia Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 261. Rest of Asia-Pacific Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 262. Rest of Asia-Pacific Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 263. Rest of Asia-Pacific Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 264. Europe Allergic Rhinitis Drugs, by Country USD Million (2019-2024)
  • Table 265. Europe Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 266. Europe Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 267. Europe Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 268. Germany Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 269. Germany Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 270. Germany Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 271. France Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 272. France Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 273. France Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 274. Italy Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 275. Italy Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 276. Italy Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 277. United Kingdom Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 278. United Kingdom Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 279. United Kingdom Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 280. Netherlands Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 281. Netherlands Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 282. Netherlands Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 283. Rest of Europe Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 284. Rest of Europe Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 285. Rest of Europe Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 286. MEA Allergic Rhinitis Drugs, by Country USD Million (2019-2024)
  • Table 287. MEA Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 288. MEA Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 289. MEA Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 290. Middle East Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 291. Middle East Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 292. Middle East Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 293. Africa Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 294. Africa Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 295. Africa Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 296. North America Allergic Rhinitis Drugs, by Country USD Million (2019-2024)
  • Table 297. North America Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 298. North America Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 299. North America Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 300. United States Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 301. United States Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 302. United States Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 303. Canada Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 304. Canada Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 305. Canada Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 306. Mexico Allergic Rhinitis Drugs, by Type USD Million (2019-2024)
  • Table 307. Mexico Allergic Rhinitis Drugs, by Application USD Million (2019-2024)
  • Table 308. Mexico Allergic Rhinitis Drugs, by Treatment USD Million (2019-2024)
  • Table 309. Allergic Rhinitis Drugs Sales: by Type(K Tons)
  • Table 310. Allergic Rhinitis Drugs Sales Corticosteroids , by Region K Tons (2019-2024)
  • Table 311. Allergic Rhinitis Drugs Sales Antihistamines , by Region K Tons (2019-2024)
  • Table 312. Allergic Rhinitis Drugs Sales Vasoconstrictors , by Region K Tons (2019-2024)
  • Table 313. Allergic Rhinitis Drugs Sales Pratropium Bromide , by Region K Tons (2019-2024)
  • Table 314. Allergic Rhinitis Drugs Sales Others [Leukotrienes, Cromoglycate] , by Region K Tons (2019-2024)
  • Table 315. Allergic Rhinitis Drugs Sales: by Application(K Tons)
  • Table 316. Allergic Rhinitis Drugs Sales Non-Allergic Rhinitis , by Region K Tons (2019-2024)
  • Table 317. Allergic Rhinitis Drugs Sales Mixed Rhinitis , by Region K Tons (2019-2024)
  • Table 318. Allergic Rhinitis Drugs Sales Seasonal Allergic Rhinitis , by Region K Tons (2019-2024)
  • Table 319. Allergic Rhinitis Drugs Sales Perennial Allergic Rhinitis , by Region K Tons (2019-2024)
  • Table 320. Allergic Rhinitis Drugs Sales Others , by Region K Tons (2019-2024)
  • Table 321. Allergic Rhinitis Drugs Sales: by Treatment(K Tons)
  • Table 322. Allergic Rhinitis Drugs Sales Oral Antihistamines , by Region K Tons (2019-2024)
  • Table 323. Allergic Rhinitis Drugs Sales Local Steroids , by Region K Tons (2019-2024)
  • Table 324. South America Allergic Rhinitis Drugs Sales, by Country K Tons (2019-2024)
  • Table 325. South America Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 326. South America Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 327. South America Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 328. Brazil Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 329. Brazil Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 330. Brazil Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 331. Argentina Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 332. Argentina Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 333. Argentina Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 334. Rest of South America Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 335. Rest of South America Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 336. Rest of South America Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 337. Asia Pacific Allergic Rhinitis Drugs Sales, by Country K Tons (2019-2024)
  • Table 338. Asia Pacific Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 339. Asia Pacific Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 340. Asia Pacific Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 341. China Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 342. China Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 343. China Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 344. Japan Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 345. Japan Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 346. Japan Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 347. India Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 348. India Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 349. India Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 350. South Korea Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 351. South Korea Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 352. South Korea Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 353. Taiwan Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 354. Taiwan Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 355. Taiwan Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 356. Australia Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 357. Australia Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 358. Australia Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 359. Rest of Asia-Pacific Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 360. Rest of Asia-Pacific Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 361. Rest of Asia-Pacific Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 362. Europe Allergic Rhinitis Drugs Sales, by Country K Tons (2019-2024)
  • Table 363. Europe Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 364. Europe Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 365. Europe Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 366. Germany Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 367. Germany Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 368. Germany Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 369. France Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 370. France Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 371. France Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 372. Italy Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 373. Italy Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 374. Italy Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 375. United Kingdom Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 376. United Kingdom Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 377. United Kingdom Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 378. Netherlands Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 379. Netherlands Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 380. Netherlands Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 381. Rest of Europe Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 382. Rest of Europe Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 383. Rest of Europe Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 384. MEA Allergic Rhinitis Drugs Sales, by Country K Tons (2019-2024)
  • Table 385. MEA Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 386. MEA Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 387. MEA Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 388. Middle East Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 389. Middle East Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 390. Middle East Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 391. Africa Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 392. Africa Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 393. Africa Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 394. North America Allergic Rhinitis Drugs Sales, by Country K Tons (2019-2024)
  • Table 395. North America Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 396. North America Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 397. North America Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 398. United States Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 399. United States Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 400. United States Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 401. Canada Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 402. Canada Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 403. Canada Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 404. Mexico Allergic Rhinitis Drugs Sales, by Type K Tons (2019-2024)
  • Table 405. Mexico Allergic Rhinitis Drugs Sales, by Application K Tons (2019-2024)
  • Table 406. Mexico Allergic Rhinitis Drugs Sales, by Treatment K Tons (2019-2024)
  • Table 407. Allergic Rhinitis Drugs: by Type(USD/Units)
  • Table 408. Research Programs/Design for This Report
  • Table 409. Key Data Information from Secondary Sources
  • Table 410. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Allergic Rhinitis Drugs: by Type USD Million (2013-2018)
  • Figure 5. Global Allergic Rhinitis Drugs: by Application USD Million (2013-2018)
  • Figure 6. Global Allergic Rhinitis Drugs: by Treatment USD Million (2013-2018)
  • Figure 7. South America Allergic Rhinitis Drugs Share (%), by Country
  • Figure 8. Asia Pacific Allergic Rhinitis Drugs Share (%), by Country
  • Figure 9. Europe Allergic Rhinitis Drugs Share (%), by Country
  • Figure 10. MEA Allergic Rhinitis Drugs Share (%), by Country
  • Figure 11. North America Allergic Rhinitis Drugs Share (%), by Country
  • Figure 12. Global Allergic Rhinitis Drugs: by Type K Tons (2013-2018)
  • Figure 13. Global Allergic Rhinitis Drugs: by Application K Tons (2013-2018)
  • Figure 14. Global Allergic Rhinitis Drugs: by Treatment K Tons (2013-2018)
  • Figure 15. South America Allergic Rhinitis Drugs Share (%), by Country
  • Figure 16. Asia Pacific Allergic Rhinitis Drugs Share (%), by Country
  • Figure 17. Europe Allergic Rhinitis Drugs Share (%), by Country
  • Figure 18. MEA Allergic Rhinitis Drugs Share (%), by Country
  • Figure 19. North America Allergic Rhinitis Drugs Share (%), by Country
  • Figure 20. Global Allergic Rhinitis Drugs: by Type USD/Units (2013-2018)
  • Figure 21. Global Allergic Rhinitis Drugs share by Players 2018 (%)
  • Figure 22. Global Allergic Rhinitis Drugs share by Players (Top 3) 2018(%)
  • Figure 23. Global Allergic Rhinitis Drugs share by Players (Top 5) 2018(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Glaxosmithkline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Glaxosmithkline (United Kingdom) Revenue: by Geography 2018
  • Figure 27. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 28. Merck (United States) Revenue: by Geography 2018
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2018
  • Figure 31. Alcon (United States) Revenue, Net Income and Gross profit
  • Figure 32. Alcon (United States) Revenue: by Geography 2018
  • Figure 33. Adamis Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 34. Adamis Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 35. Belcher Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 36. Belcher Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 37. Dr Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 38. Dr Reddy's Laboratories (India) Revenue: by Geography 2018
  • Figure 39. Mitsubishi Tanabe Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 40. Mitsubishi Tanabe Pharma (Japan) Revenue: by Geography 2018
  • Figure 41. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 43. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 44. Pfizer (United States) Revenue: by Geography 2018
  • Figure 45. UCB (Belgium) Revenue, Net Income and Gross profit
  • Figure 46. UCB (Belgium) Revenue: by Geography 2018
  • Figure 47. Kyowo Hako Kirin (Japan) Revenue, Net Income and Gross profit
  • Figure 48. Kyowo Hako Kirin (Japan) Revenue: by Geography 2018
  • Figure 49. Stallergenes Greer (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 50. Stallergenes Greer (United Kingdom) Revenue: by Geography 2018
  • Figure 51. Global Allergic Rhinitis Drugs: by Type USD Million (2019-2024)
  • Figure 52. Global Allergic Rhinitis Drugs: by Application USD Million (2019-2024)
  • Figure 53. Global Allergic Rhinitis Drugs: by Treatment USD Million (2019-2024)
  • Figure 54. South America Allergic Rhinitis Drugs Share (%), by Country
  • Figure 55. Asia Pacific Allergic Rhinitis Drugs Share (%), by Country
  • Figure 56. Europe Allergic Rhinitis Drugs Share (%), by Country
  • Figure 57. MEA Allergic Rhinitis Drugs Share (%), by Country
  • Figure 58. North America Allergic Rhinitis Drugs Share (%), by Country
  • Figure 59. Global Allergic Rhinitis Drugs: by Type K Tons (2019-2024)
  • Figure 60. Global Allergic Rhinitis Drugs: by Application K Tons (2019-2024)
  • Figure 61. Global Allergic Rhinitis Drugs: by Treatment K Tons (2019-2024)
  • Figure 62. South America Allergic Rhinitis Drugs Share (%), by Country
  • Figure 63. Asia Pacific Allergic Rhinitis Drugs Share (%), by Country
  • Figure 64. Europe Allergic Rhinitis Drugs Share (%), by Country
  • Figure 65. MEA Allergic Rhinitis Drugs Share (%), by Country
  • Figure 66. North America Allergic Rhinitis Drugs Share (%), by Country
  • Figure 67. Global Allergic Rhinitis Drugs: by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • Glaxosmithkline (United Kingdom)
  • Merck (United States)
  • Sanofi (France)
  • Alcon (United States)
  • Adamis Pharmaceuticals (United States)
  • Belcher Pharmaceuticals (United States)
  • Dr Reddy's Laboratories (India)
  • Mitsubishi Tanabe Pharma (Japan)
  • Novartis (Switzerland)
  • Pfizer (United States)
  • UCB (Belgium)
  • Kyowo Hako Kirin (Japan)
  • Stallergenes Greer (United Kingdom)
Select User Access Type

Key Highlights of Report


Jul 2019 231 Pages 62 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Allergic Rhinitis Drugs Market Report?